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Background and purpose: To develop a class solution for prostate Stereotactic Ablative Radiotherapy
(SABR) using Volumetric Modulated Arc Therapy (VMAT).
Materials and methods: Seven datasets were used to compare plans using one 360 arc (1FA), one 210 arc
(1PA), two full arcs and two partial arcs. Subsequently using 1PA, fifteen datasets were compared using (i)
6 mm CTV–PTV margins, (ii) 8 mm CTV–PTV margins and (iii) including the proximal SV within the CTV.
Monaco™ 3.2 (Elekta™) was used for planning with the Agility™ MLC system (Elekta™).
Results: Highly conformal plans were produced using all four arc arrangements. Compared to 1FA, 1PA
resulted in significantly reduced rectal doses, and monitor units and estimated delivery times were
reduced in six of seven cases. Using 6 mm CTV–PTV margins, planning constraints were met for all fifteen
datasets. Using 8 mm margins required relaxation of the uppermost bladder constraint in three cases to
achieve adequate coverage, and, compared to 6 mm margins, rectal and bladder doses significantly
increased. Including the proximal SV required relaxation of the uppermost bladder and rectal constraints
in two cases, and rectal and bladder doses significantly increased.
Conclusions: Prostate SABR VMAT is optimal using 1PA. 6 mm CTV–PTV margins, compatible with daily
fiducial-based IGRT, are consistently feasible in terms of target objectives and OAR constraints.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 110 (2014) 298–302
Open access under CC BY-NC-ND license.Prostate cancer (PCa) is the most common cancer in European
men, accounting for over one fifth of male cancer diagnoses [1].
Escalated radiation doses in localized disease result in improved
biochemical control [2]. Ultra-hypofractionation within the con-
text of stereotactic ablative radiotherapy (SABR) is an attractive ap-
proach to dose escalation. Evidence suggests PCa has a low a/b
ratio (1.5 Gy), making it theoretically more sensitive to large dose
per fraction treatments [3].
Volumetric modulated arc therapy (VMAT) uses a linac to deli-
ver radiotherapy in one or more arcs [4]. Dose rate, gantry rotation
speed, and MLC positions are altered to create highly conformal
plans [4–6]. In comparison to IMRT, VMAT plans display at least
comparable conformity with more efficient monitor unit (MU)
use and faster delivery times [4–6].Delivering prostate SABR with VMAT is an attractive option: it
offers dose escalation, the theoretical benefits of hypofractionation,
the convenience of a few fraction treatment, together with the high
conformity, MU efficiency and rapid delivery achievable with
VMAT. While much has been published regarding VMAT in PCa
and regarding prostate SABR, very little exists in the literature
regarding the PCa SABR planning with VMAT.
This planning study assesses prostate SABR using VMAT as a key
preparatory step in facilitating future clinical studies. The impact of
different arc arrangements is assessed and CTV-PTV margins consis-
tent with daily online fiducial based image guidance and cone beam
CT (CBCT) are compared. The impact of the inclusion of the proximal
seminal vesicles (proxSV) within the CTV is also evaluated.Materials and methods
Patients and volumes
Datasets from 15 early PCa patients were chosen. Patients had
full bladders and enemas prior to scanning. The bladder, rectum
L.J. Murray et al. / Radiotherapy and Oncology 110 (2014) 298–302 299(anus to recto-sigmoid junction), femoral heads (FH), penile bulb
(PB) and bowel were contoured as organs-at-risk. The CTV was
the whole prostate gland.
Part I
Seven datasets were used. The CTV was expanded isotropically
by 6 mm to create the PTV. Each dataset was planned using four arc
arrangements:
 One full 360 arc (1FA).
 One partial 210 arc (255 ? 105; 1PA).
 Two full 360 arcs (2FA).
 Two partial arcs (210 (255 ? 105) and 180 (270 ? 90); 2PA).
Part II
Fifteen datasets were planned using 1PA and 6 mm CTV–PTV
margins, reflecting margins used with fiducial marker based daily
online image guidance (IGRT) [7–9]. All 15 datasets were re-
planned using 8 mm CTV–PTV margins, reflecting margins compat-
ible with daily cone beam CT (CBCT) (without fiducials) [10].
Part III
The fifteen datasets were re-planned including the prostate and
proximal 1 cm of SV within the CTV, expanded by 6 mm to PTV.Table 1
Dose volume constraints adopted for planning study.
Volume Constraints
Rectum V41.4 Gy (97%) < 3%
V38.4 Gy (90%) < 15%*
V32.0 Gy (75%) 6 35%*
V28.0 Gy (65%) 6 45%*
V24.8 Gy (58%) < 70%
V19.6 Gy (46%) < 80%
Bladder V41.4 Gy (97%) < 5%
V34.7 Gy (81%) < 25%
V29.9 Gy (70%) < 50%
Femoral heads Dmax 6 29.9 Gy (70%)*
V29.9 Gy (70%) < 50%
Bowel V29.9 Gy (70%) < 17 cc
Penile bulb (objective only)** V29.9 Gy (70%) < 50%
V34.7 Gy (81%) < 10%
* Dose volume constraints adopted from Hypo-RT-PC phase III trial [11]. Those
constraints without an asterisk are biologically equivalent to those used in the
CHHiP trial for 74 Gy in 37 fraction treatments [12].
** Constraints for the penile bulb were for guidance only and did not have to be
achieved.Dose and PTV coverage
The PTV dose was 42.7 Gy in 7 fractions. Compared to 78 Gy in
39 fractions (standard European prostate fractionation), this deliv-
ers a higher biologically effective dose (BED) to the prostate
(216.3 Gy vs. 182.0 Gy; a/b 1.5 Gy) but an equivalent dose to late
responding tissues (129.5 Gy vs. 130.0 Gy; a/b 3.0 Gy; see Supple-
mentary Material for further explanation).
We specified:
(i) 95% of the PTV receives at least 95% of the prescription dose
(D95% P 40.6 Gy).
(ii) Minimum prostate dose: P40.6 Gy, (Dmin P 40.6 Gy (95%)).
(iii) Dose received by 99% of the PTV: P38.4 Gy (D99% P 38.4 Gy
(90%)).
(iv) Maximum dose: 6120% (Dmax 51.2 Gy).
(v) Conformity index (to limit high dose spill; CI; see below)
should be less than 1.2.
(vi) Where feasible, dose received by 98% of the PTV: P95% of
the PD (D98% P 95%) and dose received by 2% of the PTV:
6107% (D2% 6 107%).
As SABR generally encourages dose escalation, it was acceptable
if the median dose exceeded the prescription dose of 42.7 Gy.
Defining organ-at-risk constraints
The appropriate organ-at-risk constraints for prostate SABR are
unknown. The Hypo-RT-PC trial, a phase III trial comparing 42.7 Gy
in 7 fractions with 78 Gy in 39 fractions delivered using IMRT or
3D-CRT, specifies three rectal constraints for the SABR schedule
covering high and intermediate doses [11]. Additional constraints
were employed to cover the very high and low dose regions, which
were biologically equivalent to those used in the 74 Gy in 37 frac-
tions arm of the UK CHHiP trial (which reported low 2-year grade
2+ bowel and bladder toxicity at 4.3% and 2.2%, respectively
[12,13]) (Table 1; See Supplementary Material for further
explanation).
Biologically equivalent constraints to 74 Gy in 37 fractions for a
7 fraction schedule were also derived for bladder, FH, bowel and PB
(Table 1).Planning and evaluation
Monaco 3.2 (Elekta™) with a Monte Carlo (MC) calculation,
Agility 5 mm MLC system (Elekta™), 150 control points per arc,
1% MC variance per plan, 6 MV photons and a 3 mm calculation
grid were employed.
The following were recorded:
 CTV: median dose (D50%), D2%, D98% and volume receiving
100% of PD (V100%).
 PTV: D50%, D2%, D98% and D95%.
 Organ-at-risk mean doses and D2%, volume of rectum and blad-
der receiving at least 95% (V95%), 80% (V80%), 50% (V50%) and
20% (V20%) of PD to reflect very high, high, intermediate and
low doses, respectively.
 CI: volume of 95% isodose/PTV volume [14].
 Conformation number (CN): (volume of PTV receiving 95% iso-
dose/PTV volume)  (volume of PTV receiving 95% isodose/vol-
ume of 95% isodose) [14].
 Homogeneity index (HI): (D2–D98%)/D50% [15].
 R50: volume of 50% isodose/PTV volume.
 Maximum dose 2 cm from PTV (Dmax 2 cm).
 MU per fraction.
 Estimated delivery time (EDT).
Statistics
The Wilcoxon signed-rank test was used to compare parame-
ters as data were not normally distributed. Median values and
ranges are therefore presented. SPSS v19.0 was used for calcula-
tions. Tests were two-tailed.
Multiple statistical comparisons are made but a full Bonferroni
correction would be over-conservative as several tests are not
independent. In part I of the study, the small sample size limits
the degree of statistical significance achievable. As a pragmatic ap-
proach, p 6 0.02 was considered statistically significant for part I of
the study, and p 6 0.005 was considered significant in parts II and
III.Results
Part I: arc arrangements
Adequate CTV (prostate only) and PTV coverage was achieved
and organ-at-risk constraints were met using all arc arrangements
300 Prostate SABR VMAT(Fig. 1a–d in Supplementary Material). Plans were highly confor-
mal with CI <1.2 and CN P0.81, and doses were homogeneous
(HI: 0.08–0.12). Compared to 1FA, there were no significant differ-
ences in CTV and PTV coverage with different arc arrangements,
with the exception of 2FA, where there was a significant reduction
in CTV V100% (1FA vs. 2FA: 97.9% vs. 95.2%, p = 0.016; median val-
ues presented) and a statistically significant, but clinically insignif-
icant, reduction in PTV D50% (43.5 Gy vs. 43.4 Gy, p = 0.016, Table 4
in Supplementary Material).
Compared to 1FA, partial arc arrangements resulted in signifi-
cant reductions in rectal mean dose (1FA vs. 1PA: 15.1 Gy vs.
13.2 Gy, p = 0.016, 1FA vs. 2PA: 15.1 Gy vs. 13.0 Gy, p = 0.016),
V50% and V20%, (Fig. 1a, Table 4 in Supplementary Material). Com-
pared to 1FA, there were no statistically significant differences in
bladder doses. Partial arc arrangements resulted in significant in-
creases in FH mean doses and D2% (Table 4 in Supplementary
Material), although doses remained well within tolerance. A statis-
tically significant, but clinically insignificant, increase in R50
occurred using 2FA (3.7 vs. 3.9, p = 0.016). Compared to 1FA, 1PA re-
sulted in reduced EDTs in 6 of 7 cases but this result did not reach
our selected level for statistical significance (173 s vs. 152 s,
p = 0.047). Similarly, compared to 1FA, 1PA resulted in reduced
MU requirements in 6 of 7 cases but this also did not reach statisti-
cal significance (2049 MU vs. 1785 MU, p = 0.031). There was a sig-
nificant increase in EDT using 2FA (173 s vs. 206 s, p = 0.016). See
Tables 4–7 in Supplementary Material for full planning data.
Given target coverage and conformity equivalence, significant
reductions in rectal mean dose, V50% and V20%, together with
the MU and EDT advantages, the 210 partial arc was selected for
further investigation.Part II: CTV–PTV margins
Fifteen datasets were planned using 1PA and 6 mm CTV–PTV
margins. Adequate CTV and PTV coverage was achieved and or-
gan-at-risk constraints were met, and were generally well within
desired limits (Fig. 1b).
Datasets were re-planned using 1PA and 8 mm CTV–PTV mar-
gins (Fig. 1e in Supplementary Material). In 12 cases (80%) it was
possible to achieve CTV and PTV coverage and meet organ-at-risk
constraints. In three cases it was necessary to relax the uppermost
bladder constraint (V41.4 Gy <5%) to up to 8.7% to achieve ade-
quate coverage. Other bladder constraints were achieved. There
was a small reduction in homogeneity using 8 mm margins
(6 mm vs. 8 mm HI: 0.11 vs. 0.13, p < 0.001).
Of the three patients where the uppermost bladder constraint
had to be relaxed, two had median lobes protruding into the blad-
der and relatively small bladder volumes (208 ml and 249 ml). The
third patient had a very large median lobe and the largest volume
prostate in the series (60.0 cm3).
Compared to plans using 6 mm CTV–PTV margins, there was no
significant difference in CTV and PTV D50% although 8 mm mar-
gins resulted in a small but significant reductions in PTV D95%
(41.4 Gy vs. 40.8 Gy, p < 0.001, Fig. 1b, Fig. 2a in Supplementary
Material), and PTV D98% (40.6 Gy vs. 40.0 Gy, p = 0.001), and signif-
icant increases in rectal and bladder mean doses and V95%, V80%,
V50% and V20% (Fig. 1b, Table 5 in Supplementary Material). There
were statistically significant, but clinically insignificant, increases
in mean bowel dose using 8 mm margins. There was also a signif-
icant increase in right mean FH dose, but this remained well within
tolerance, as well as an increase in PB mean dose and D2% (Table 5
in Supplementary Material).
There was no significant difference in CI, which considers 95%
isodose and PTV volumes (but not PTV coverage), nor CN, which
reflects PTV coverage as well as high dose spill.Part III: inclusion of proxSV
Datasets were re-planned using 1PA and 6 mm CTV–PTV
margins but including the proxSV within the CTV (Fig. 1f in
Supplementary Material). In 13 cases CTV and PTV coverage was
achieved and all organ-at-risk constraints were met. In two cases
(13%; the same two cases with small bladder volumes and median
lobe hypertrophy requiring relaxation of the uppermost bladder
constraints using 8 mm CTV–PTV margins) it was necessary to re-
lax the uppermost bladder and rectal constraints up to 6.6% and
3.9%, respectively to achieve coverage. Other constraints were
met. It was possible to re-plan both to achieve coverage and
meet all constraints by defining two PTVs: prostate plus 6 mm,
prescribed 42.7 Gy, and prostate and proximal 1 cm of SV plus
6 mm, prescribed 32.4 Gy (76%).
Adequate CTV and PTV coverage was achieved although, com-
pared to treating prostate alone, there were small but significant
reductions in PTV D95% (41.4 Gy vs. 40.9 Gy, p = 0.001, Fig 1c,
Fig. 2b in Supplementary Material) and PTV D98% (40.6 Gy vs.
40.2 Gy, p < 0.001) and a small increase in CTV D2% (45.9 Gy vs.
46.4 Gy, p = 0.001). The bladder and rectum received significantly
higher mean doses and V80%, V50% and V20% (Fig. 1c, Table 5 in
Supplementary Material). There were significant increases in left
FH D2%, and bowel mean dose and D2%, although these remained
well within tolerance (Table 5 in Supplementary Material). Com-
pared to treating the prostate alone, plans were less homogeneous
(prostate alone vs. prostate + SV HI: 0.11 vs. 0.13, p < 0.001) and
required increased MU. (1814 vs. 1910 MU, p = 0.002).Discussion
Much has been published regarding the use of VMAT in PCa, and
regarding SABR in PCa. There is, however, very little in the litera-
ture, regarding the optimal planning of prostate SABR using VMAT.
It is important and relevant to develop linac-based solutions for
prostate SABR as this delivery method is more widely available
than alternatives such as Cyberknife™ (Accuray™). We found pros-
tate SABR planned with VMAT is optimal using 1PA. Using 6 mm
CTV–PTV margins, compatible with daily fiducial based IGRT, is
consistently feasible in terms of target objectives and organ-at-risk
constraints. All arc arrangements investigated resulted in highly
conformal plans but a single 210 partial arc was preferred: confor-
mity was maintained while rectal mean dose, V50% and V20% were
reduced and most patients also benefitted in terms of EDT and MU
requirements. FH doses increased but remained well within
tolerance.
The optimal organ-at-risk constraints for prostate SABR remain
unknown. In this study we adopted constraints from the HYPO-
RT-PC trial and added additional constraints which were biologi-
cally equivalent to those used in the CHHiP trial which reported
low 2-year toxicity [11–13].
In the Hypo-RT-PC trial, which employs the same SABR dose, no
constraint is specified for very high rectal doses, and there are no
bladder constraints [11]. Several of the Cyberknife™ prostate SABR
trials stipulate that rectal V100% should not exceed 5% and do not
specify very high bladder dose constraints [16–18]. Our study
specified a 3% restriction on rectal V97% and a 5% restriction on
bladder V97%. Our approach, therefore, may be considered conser-
vative. With a new technique, however, caution is appropriate. Fur-
thermore, when uppermost constraints were met, or minimally
exceeded, in our study, all lower constraints were more than ade-
quately achieved. This may translate into low late toxicity rates
when these constraints are employed clinically. Caution must be
exercised, however, when comparing the constraints adopted be-
tween studies as the length of contoured rectum may differ, and
this should be specified to aid meaningful comparisons.
   *         *          *    *   *         *          *    * 
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Fig. 1. (a) Rectal DVH using four beam arrangements (median values plotted). ⁄Rectal V20% and V50% for one partial arc and two partial arcs significantly less than one full arc
(p < 0.02). (b) DVH comparisons for 6 mm and 8 mm CTV to PTV margins (median values plotted). PTV D95% significantly less using 8 mm margins compared to 6 mm
margins (p < 0.005). ⁄Rectal/bladder V20%, V50%, V80% and V95% significantly less using 6 mm vs. 8 mm margins (p < 0.005). (c) DVH comparisons for CTV containing prostate
alone and CTV containing prostate + proximal seminal vesicles (median values plotted), SV: seminal vesicles. PTV D95% significantly less with prostate + proximal seminal
vesicles in CTV compared to prostate alone (p < 0.005). ⁄Rectal/bladder V20%, V50%, and V80% significantly less with prostate alone in CTV compared to prostate plus proximal
seminal vesicles (p 6 0.005).
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ized PCa is mainly in the form of small trials or series, 13 using
Cyberknife™ and 6 using linacs [18–24]. There is variation in
dose-fractionation schedules, organ-at-risk constraints, use of
androgen deprivation, CTV–PTV margins, IGRT techniques and
inclusion of SV within the CTV (most often the SV are not treated,
even in non-low risk patients). Overall, toxicity rates and PSA con-
trol appear encouraging.
Delivering prostate SABR using VMAT has not been widely prac-
ticed. Two groups report production and delivery of SABR VMAT
plans [25,26]. Agazaryan et al., using RapidArc VMAT (Varian) for
10 patients, delivering 40 Gy in 5 fractions, found two full arcs re-
sulted in improved homogeneity and conformity compared to one.
It is currently uncertain whether homogenous or heterogeneous
dose distributions are preferable. Our planning study aimed for a
degree of homogeneity where feasible. In contrast to the RapidArc
study, our study found no significant improvement in homogeneity
or conformity using 2 arcs which may relate to differences in the
planning algorithms and linac delivery associated with each
technique.
Miften et al. delivered 50 Gy in 5 fractions to 6 patients mainly
using 1FA [26]. CI ranged from 1.09 to 1.21, CN from 0.75 to 0.82
and treatment times from 8 to 13 min. Our study demonstrated
similar CI, slightly improved CN, and EDT were shorter than those
measured by Miften et al. We have also delivered 3 1PA treat-
ments, with measured delivery times of 196, 203 and 213 s per
fraction.
Robust IGRT is required for SABR. Several SABR trials employ
intra-fraction motion tracking and correction, allowing small
CTV–PTV margins (3–5 mm) [16,18,20,24]. We evaluated 6 mm
margins which are sufficient to account for residual set-up inac-
curacy and uncorrected intra-fraction motion when using fiducial
markers for daily online IGRT [7–9]. Larger CTV–PTV marginscarry the risk of increased toxicity but with 6 mm margins,
planning was successful in terms of coverage and organ-at-risk
constraints.
CBCT (without fiducials) is an alternative IGRT technique. Given
uncertainties and inter-observer variability, CTV–PTV margins of
about 8 mm are required [10]. When planning with 8 mm margins,
although PTV coverage was adequate, there was a small but signif-
icant reduction in D95%, and significant increases in rectal and
bladder mean doses and in volumes receiving very high, high,
intermediate and low doses. Furthermore, in 3 patients (20%) it
was necessary to relax the uppermost bladder constraint to
achieve coverage: two had small bladder volumes and median lobe
hyperplasia and one had the largest volume prostate in the series
and a very large median lobe (all resulting in a larger proportion
of bladder within or close to the PTV). The clinical consequences
of such bladder overdoses are unknown [27]. Since 6 mm margins
were consistently feasible in terms of organ-at-risk constraints,
then implanted fiducial markers, and the accompanying smaller
CTV–PTV margins, should be used in preference.
When including the proxSV in the CTV, and using 6 mm
CTV–PTV margins, a potential solution for patients with early
intermediate risk disease, although PTV coverage was adequate,
there was a small but significant reduction in D95% and significant
increases in rectal and bladder mean doses and in volumes receiv-
ing high, intermediate and low doses. Furthermore, in 13% of cases
it was necessary to relax the uppermost bladder and rectal con-
straints. Ensuring full bladders and using biodegradable spacers
to increase prostate to rectal distance could potentially allow prox-
SV inclusion, without exceeding constraints [28]. The use of neo-
adjuvant hormone deprivation could also facilitate planning. An-
other strategy is to create two PTVs (prostate and prostate plus
proxSV) and prescribe a reduced dose to the prostate plus SV
PTV. Given that constraints could not be met consistently when
302 Prostate SABR VMATincluding the proximal 1 cm of SV, it is unlikely that prescribing
the same dose to greater lengths of SV would be feasible, thus
excluding higher risk patients from this linac based treatment
option. Treating the prostate alone, as in most of the existing SABR
trials, appears likely to be the safest option.
In conclusion, delivering prostate SABR using VMAT offers dose
escalation, the theoretical benefits of hypofractionation, the conve-
nience of a few fraction treatment, and the highly conformal plans,
MU efficiency and rapid delivery achievable with VMAT. We have
demonstrated that prostate SABR planning using VMAT is consis-
tently feasible when treating the prostate alone using 6 mm
CTV–PTV margins, compatible with fiducial marker daily online
IGRT. A 210 arc was optimal. Clinical trials are required to evalu-
ate this technique in practice.Conflict of interest statement
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